October 2016

Dear Customer,

GlaxoSmithKline (GSK) has made the decision to discontinue the manufacture and sale of MenHibrix® [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine] in the US. This decision was made due to low demand for the vaccine and the resulting opportunity to shift GSK vaccine production capacity to other GSK vaccines with greater customer demand. MenHibrix will continue to be available to order through February 2017 or until inventory levels are depleted (whichever occurs first), at which point, GSK will discontinue availability of the vaccine (see information below).

<table>
<thead>
<tr>
<th>Product</th>
<th>NDC</th>
<th>Presentation</th>
<th>Final Lot</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>MenHibrix® [Meningococcal Groups C and Y and Haemophilus b Tetanus</td>
<td>58160-801-11</td>
<td>Single-dose vials of lyophilized vaccine, accompanied by vials containing 0.85</td>
<td>T2T33</td>
<td>September 17, 2017</td>
</tr>
<tr>
<td>Toxoid Conjugate Vaccine]</td>
<td>(package of 10 doses)</td>
<td>mL of saline diluent</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In the US, GSK has alternative vaccines that are available for use against MenACWY and Hib in infants. The last day to order MenHibrix will be 2/28/17 and GSK’s last ship date will be 3/1/17 (or until inventory levels are depleted, whichever occurs first).

If you have any questions or need assistance, please contact Customer Service at 1-800-877-1158.

Sincerely,

Pascal Prigent
VP Marketing Operations

MenHibrix is a registered trademark of the GSK group of companies.
Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.